Thermo Fisher Acquires Rights to Preeclampsia Biomarker from Nephromics | GenomeWeb

Thermo Fisher Scientific said this week it has acquired the exclusive rights from diagnostics firm Nephromics to use placental growth factor protein as a biomarker for the diagnosis of preeclampsia and eclampsia.

The company will develop PLGF as an immunoassay on its Kryptor platform, complementing its existing prenatal screening products, which include assays for PAPP-A, free βhCG, and AFP. It said it plans to launch the test in the first quarter of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.